T1	Participants 101 129	metastatic colorectal cancer
T2	Participants 166 214	southern Italy cooperative oncology group trials
T3	Participants 434 468	metastatic colorectal cancer (CRC)
T4	Participants 510 522	254 patients
T5	Participants 1738 1798	regimen was effective and well tolerated by elderly patients
T6	Participants 1539 1723	Patients with no weight loss and/or preserved PS and with a limited disease extent appeared to obtain the greatest benefit from our irinotecan/5-FU/LV regimen, with acceptable toxicity
